Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial

An amended protocol has been submitted to the FDA to expand enrolment to approximately 44,000 participants which also allows for enrolment of new populations – adolescents, people with chronic, stable HIV, hepatitis B/C, as well as provide additional safety and efficacy data.


Biospace Inc.